PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25403620-0 2015 Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. montelukast 0-11 cysteinyl leukotriene receptor 1 Rattus norvegicus 15-47 26497763-6 2015 Intestinal IRI induced a marked increase in CysLTR1, Caspase-8 and -9 expression in intestine, liver and kidney, which were markedly reduced by preconditioning with 2 mg/kg montelukast. montelukast 173-184 cysteinyl leukotriene receptor 1 Rattus norvegicus 44-51 26989383-1 2015 BACKGROUND: Montelukast is a cysteinyl-leukotriene type 1 (CysLT1) selective receptor antagonist. montelukast 12-23 cysteinyl leukotriene receptor 1 Rattus norvegicus 29-57 26989383-1 2015 BACKGROUND: Montelukast is a cysteinyl-leukotriene type 1 (CysLT1) selective receptor antagonist. montelukast 12-23 cysteinyl leukotriene receptor 1 Rattus norvegicus 59-65 25403620-3 2015 Therefore it seemed interesting to study the possible neuroprotective effect of Montelukast, a CysLTR1 antagonist in global cerebral ischemia/reperfusion (IR) injury in rats. montelukast 80-91 cysteinyl leukotriene receptor 1 Rattus norvegicus 95-102 26442542-3 2015 The present study was designed to investigate the role of montelukast, a selective reversible CysLT1 receptor antagonist, on spinal cord I/R injury in an experimental model. montelukast 58-69 cysteinyl leukotriene receptor 1 Rattus norvegicus 94-100 22449377-1 2012 In addition to antiasthmatic effect, the cysteinyl leukotriene receptor 1 (CysLT1) antagonist montelukast shows renoprotective effect during ischemia/reperfusion and cyclosporine-induced renal damage. montelukast 94-105 cysteinyl leukotriene receptor 1 Rattus norvegicus 41-73 24494466-0 2013 Protective effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against intestinal ischemia-reperfusion injury in the rat. montelukast 21-32 cysteinyl leukotriene receptor 1 Rattus norvegicus 36-68 22449377-1 2012 In addition to antiasthmatic effect, the cysteinyl leukotriene receptor 1 (CysLT1) antagonist montelukast shows renoprotective effect during ischemia/reperfusion and cyclosporine-induced renal damage. montelukast 94-105 cysteinyl leukotriene receptor 1 Rattus norvegicus 75-81 22449377-11 2012 The results of this work are expected to open new avenues for early prevention of rhabdomyolysis-induced acute renal failure using selective CysLT1 antagonists such as montelukast. montelukast 168-179 cysteinyl leukotriene receptor 1 Rattus norvegicus 141-147 22723160-1 2012 OBJECTIVE: To determine the effect of montelukast, a cysteinyl leukotriene receptor 1 antagonist, on morphological changes in rat neurons after ischemic injury. montelukast 38-49 cysteinyl leukotriene receptor 1 Rattus norvegicus 53-85 24692820-3 2008 Montelukast is a selective reversible cysteinyl leukotriene receptor-1 antagonist that has been found to have protective effects against renal ischemia reperfusion injury and burn-induced oxidative injury of the skin in rats. montelukast 0-11 cysteinyl leukotriene receptor 1 Rattus norvegicus 38-70 19589545-2 2009 Using an inferior epigastric artery skin flap as a flap ischemia/reperfusion (I/R) injury model, we investigated whether the administration of montelukast sodium, a selective reversible cysteinyl leukotriene 1 (CysLT1) receptor antagonist, decreases neutrophil infiltration and promotes flap survival. montelukast 143-161 cysteinyl leukotriene receptor 1 Rattus norvegicus 186-209 19589545-2 2009 Using an inferior epigastric artery skin flap as a flap ischemia/reperfusion (I/R) injury model, we investigated whether the administration of montelukast sodium, a selective reversible cysteinyl leukotriene 1 (CysLT1) receptor antagonist, decreases neutrophil infiltration and promotes flap survival. montelukast 143-161 cysteinyl leukotriene receptor 1 Rattus norvegicus 211-217 19589545-13 2009 CONCLUSION: This study suggests that montelukast CysLT1 receptor antagonist montelukast reversed I/R-induced oxidant responses and improved flap survival by inhibiting neutrophil infiltration and balancing oxidant and antioxidant status. montelukast 37-48 cysteinyl leukotriene receptor 1 Rattus norvegicus 49-55 20467345-0 2010 Montelukast, a selective cysteinyl leukotriene receptor 1 antagonist, reduces cerulein-induced pancreatic injury in rats. montelukast 0-11 cysteinyl leukotriene receptor 1 Rattus norvegicus 25-57 21105577-5 2010 We found that the microvessel growth in 25% serum-containing cultures was significantly inhibited by the CysLT1 receptor antagonist montelukast (0.1-1 microM), but not by the CysLT2 receptor antagonist BAY cyslt2 (0.1-1 microM). montelukast 132-143 cysteinyl leukotriene receptor 1 Rattus norvegicus 105-111 19515388-2 2010 This study was designed to assess the possible protective effect of montelukast, a selective antagonist of cysteinyl leukotriene receptor 1 (CysLT1), on hepatic I/R injury in rats. montelukast 68-79 cysteinyl leukotriene receptor 1 Rattus norvegicus 107-139 19515388-2 2010 This study was designed to assess the possible protective effect of montelukast, a selective antagonist of cysteinyl leukotriene receptor 1 (CysLT1), on hepatic I/R injury in rats. montelukast 68-79 cysteinyl leukotriene receptor 1 Rattus norvegicus 141-147 30222980-1 2018 Montelukast (MK),a cysteinyl leukotriene (CysLT1) receptor antagonist, latterly exhibited a remarkable neuroprotective activity in various neurodegenerative disorders. montelukast 0-11 cysteinyl leukotriene receptor 1 Rattus norvegicus 42-48 12227087-1 2002 Montelukast sodium, a specific leukotriene receptor (CysLT1) blocker administered orally in a dose of 40 mg/kg prevented the stomach mucosa in rats from acute erosive gastritis model induced by acetylsalicylic acid (150 mg/kg, p.o.) montelukast 0-18 cysteinyl leukotriene receptor 1 Rattus norvegicus 53-59 17499745-0 2007 Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast. montelukast 118-129 cysteinyl leukotriene receptor 1 Rattus norvegicus 91-97 17499745-2 2007 We aimed to investigate the possible protective effect of montelukast, a CysLT1 receptor antagonist, against oxidative damage in a rat model of CRF, induced by 5/6 reduction of renal mass. montelukast 58-69 cysteinyl leukotriene receptor 1 Rattus norvegicus 73-79 17173892-0 2007 Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist. montelukast 64-75 cysteinyl leukotriene receptor 1 Rattus norvegicus 101-107 17173892-2 2007 The present study aimed to investigate the possible protective effect of montelukast, a selective antagonist of cysteinyl leukotriene receptor 1 (leukotriene CysLT1), against Escherichia coli-induced oxidative injury and scarring in renal tissue. montelukast 73-84 cysteinyl leukotriene receptor 1 Rattus norvegicus 158-164 17173892-11 2007 Leukotriene CysLT1 receptor antagonist montelukast reversed all these biochemical indices, as well as histopathological alterations, that were induced by acute pyelonephritis. montelukast 39-50 cysteinyl leukotriene receptor 1 Rattus norvegicus 12-18 17173892-12 2007 It seems likely that montelukast protects kidney tissue by inhibiting neutrophil infiltration, balancing oxidant-antioxidant status, and regulating the generation of inflammatory mediators suggesting a future role for leukotriene CysLT1 receptor antagonists in the treatment of pyelonephritis. montelukast 21-32 cysteinyl leukotriene receptor 1 Rattus norvegicus 230-236 16584888-2 2006 OBJECTIVE: This study was designed to assess the possible protective effect of montelukast, a selective antagonist of cysteinyl leukotriene receptor 1 (CysLT1), on renal I/R injury. montelukast 79-90 cysteinyl leukotriene receptor 1 Rattus norvegicus 118-150 16584888-2 2006 OBJECTIVE: This study was designed to assess the possible protective effect of montelukast, a selective antagonist of cysteinyl leukotriene receptor 1 (CysLT1), on renal I/R injury. montelukast 79-90 cysteinyl leukotriene receptor 1 Rattus norvegicus 152-158 16584888-11 2006 CONCLUSIONS: CysLT1 receptor antagonist montelukast reversed I/R-induced oxidant responses, improved microscopic damage and renal function. montelukast 40-51 cysteinyl leukotriene receptor 1 Rattus norvegicus 13-19 12418588-6 2002 In summary, treatment with the cysLT1 receptor antagonist montelukast reduced the inflammatory response during development of an eosinophilic airway inflammation, possibly by inhibiting the release of pro-inflammatory mediators like ET-1 and IFN-gamma. montelukast 58-69 cysteinyl leukotriene receptor 1 Rattus norvegicus 31-37 35013876-2 2022 Montelukast, a well-known cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is widely used for the anti-inflammatory management of asthma. montelukast 0-11 cysteinyl leukotriene receptor 1 Rattus norvegicus 26-58 31309487-2 2019 We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis. montelukast 45-56 cysteinyl leukotriene receptor 1 Rattus norvegicus 66-98 31309487-2 2019 We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis. montelukast 45-56 cysteinyl leukotriene receptor 1 Rattus norvegicus 100-106 30222980-1 2018 Montelukast (MK),a cysteinyl leukotriene (CysLT1) receptor antagonist, latterly exhibited a remarkable neuroprotective activity in various neurodegenerative disorders. montelukast 13-15 cysteinyl leukotriene receptor 1 Rattus norvegicus 42-48 27881050-5 2016 Montelukast targets leukotriene receptors GPR17 and CysLTR1 and appears to invert leukotriene signaling, converting an inflammatory signal into an anti-inflammatory signal. montelukast 0-11 cysteinyl leukotriene receptor 1 Rattus norvegicus 52-59 27909742-0 2017 The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate. montelukast 32-43 cysteinyl leukotriene receptor 1 Rattus norvegicus 47-79 27909742-2 2017 The current study was aimed to investigate the effect of montelukast, an antagonist of cysteinyl leukotriene receptor-1, against estrogen-induced, nonbacterial lateral lobe-specific prostate inflammation in rats. montelukast 57-68 cysteinyl leukotriene receptor 1 Rattus norvegicus 87-119